NEUROON-MED SIGNED
NEUROON-MED – the future of at-home diagnosis of sleep disorders
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0NEUROON-MED project word cloud
Explore the words cloud of the NEUROON-MED project. It provides you a very rough idea of what is the project "NEUROON-MED" about.
Project "NEUROON-MED" data sheet
The following table provides information about the project.
| Coordinator |
INTELICLINIC SP. Z.O.O.
Organization address contact info |
| Coordinator Country | Poland [PL] |
| Project website | https://neuroonopen.com/ |
| Total cost | 2˙321˙250 € |
| EC max contribution | 1˙624˙875 € (70%) |
| Programme |
1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) |
| Code Call | H2020-SMEINST-2-2016-2017 |
| Funding Scheme | SME-2 |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-06-01 to 2020-05-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | INTELICLINIC SP. Z.O.O. | PL (WARSZAWA) | coordinator | 1˙624˙875.00 |
Map
Project objective
More than 100 million people suffer from sleep apnea (SA) worldwide according to the WHO data. People with SA have a life expectancy 20 years shorter than the average life span. Additionally, they have a three- to sevenfold increased risk of motor vehicle crashes. The economic impact of sleep disorders is massive, specialists from the Harvard School of medicine calculated that costs of SA only in the US accounts for $115 billion every year. The main problem the world is facing with stopping the SA epidemic is not a treatment but diagnosis. It is estimated that 85% of people who suffer from SA have never been diagnosed. The reason for the low screening rate of SA is a limited access to polysomnography (PSG) – the gold standard for testing sleep disorders. At Inteliclinic, we have developed the NeuroOn-MED mask which is addressing the customers need for effective and inexpensive solution for home diagnosis of SA. Our advantage over competitors is built upon the technological excellence of NeuroOn-MED, which analyses the brainwaves and eye movements in the same way as PSG does. The sensors of NeuroOn-MED (EEG, EOG, pulse oximetry, and others) combined with artificial intelligence algorithms for sleep data analysis provide 90% of PSG effectiveness, allowing for distinguishing between sleep stages and various variants of SA. Comparing with the currently offered home sleep monitors which are capable only of diagnosing moderate and severe SA cases. Moreover, the price of our device will be lower than currently offered solutions. NeuroOn-MED is perfectly aligned with new trends in remote diagnosis of sleep disorders. The market of SA diagnostic devices is expected to reach a value of $7.3 billion in 2018, with a CAGR of 15.0%. The proposed SMEI-funded project will be focused on clinical studies of the NeuroOn-MED, which will lead to registration as a medical device and fast commercialisation on European and US markets in 2019-20.
Deliverables
| NeuroOn-MED product specification | Documents, reports | 2020-01-31 16:50:17 |
Take a look to the deliverables list in detail: detailed list of NEUROON-MED deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEUROON-MED" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NEUROON-MED" are provided by the European Opendata Portal: CORDIS opendata.